Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Bullboard (CSE:AGN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by StockHawk1on Jan 16, 2023 6:01pm

AGN on The Power Play to dicuss Phase 2b Ifenprodi study

Algernon Pharmaceuticals (AGN.c AGNPF) featured on The Power Play after announcing plans for a Phase 2b clinical study of their Ifenprodi drug for chronic cough. AGN plans to start the 180-patient 90 ...more  
170
Post by SkywalkerofLukeon Jan 16, 2023 5:03pm

Recent News

After completing the Phase 2a study of Ifenprodil and seeing significant positive results, AGN.c AGNPF announced last week a 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough ...more  
153
Comment by C10H12N2on Jan 14, 2023 6:27pm

RE:Exposing Longtime Shill Who Acts Brand New @ stocktwits.com

$AGNPF Broke_Horse The Troll, inquiring minds want to know… if you hate the stock, and the members on every AGN/AGNPF message board that you troll hate you… why stick around for years posting lies, bs ...more  
108
Discussion
Post by C10H12N2on Jan 14, 2023 10:25am

Lest Anyone Forget...

but for the Draconian (Dracula Blood) 100/1 Reverse Split, the stock would likely be trading at less than 1 Cent.  
161
Post by StockHawk1on Jan 13, 2023 5:55pm

Phase 2b Ifenprodi study to begin in Q3

Algernon Pharmaceuticals (AGN.c AGNPF) to start its Phase 2b clinical study of Ifenprodi for the treatment of chronic cough in Q3 of 2023. This study comes after the Phase 2a study which showed ...more  
160
Post by XeniaTechieon Jan 13, 2023 2:15pm

Leading chronic cough expert joins AGN advisory board

The appointment of Dr. Peter Dicpinigaitis MD as a medical consultant to Algernon Pharmaceuticals' chronic cough research program is pretty significant. Dr. Dicpinigaitis is the founder and ...more  
131
Post by C10H12N2on Jan 13, 2023 9:16am

Your (4th) CEO Has Diluted AGN By 12.5 Times Over In 4 Years

...Not Including Any Current Offerings To Date. Carry On
133
Post by StockHawk1on Jan 12, 2023 2:56pm

AGN DMT research featured in the Green Market Report

Algernon Pharmaceuticals (AGN.c AGNPF) is up on the CSE again today The pharma development company was featured in The Green Market Report for its research on DMT for the treatment of stroke ...more  
94
Post by XeniaTechieon Jan 12, 2023 1:25pm

Is Ifenprodil the next billion dollar cough drug?

Algernon Pharmaceuticals recently received FDA Orphan Drug Designation for Ifenprodil in IPF treatment & CEO Christopher Moreau shares an update for a new Phase 2B study slated to commence in July ...more  
139
Comment by C10H12N2on Jan 12, 2023 9:09am

RE:Chronic Cough Trials

What Christopher Moreau (CEO) says and what actually happens tends not to usually align with what one would assume. Thus, I've clearly stated the "multinational" clinical trial(s) have ...more  
100
Discussion
Comment by C10H12N2on Jan 12, 2023 8:59am

RE:RE:Dr. Peter Dicpinigaitis Appointed to the Advisory Board

Please let us all know how the date goes.
43
Discussion
Post by nodaytraderon Jan 11, 2023 8:49pm

Chronic Cough Trials

In response to recent comments: 1. Christopher Moreau has stated that AGN's chronic cough study will mirror the Merck and Bellus studies so that direct comparisons can be made. 2. The study will ...more  
207
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities